Healthcare Industry News: colonoscopy
News Release - March 9, 2007
CT Colonography Study Demonstrates Effectiveness of Medicsight CAD for Colorectal Cancer Detection in Symptomatic PatientsLONDON, March 9 (HSMN NewsFeed) -- Medicsight plc, a subsidiary company of MGT Capital Investments, Inc. (Amex: MGT ), announced today the presentation of a study demonstrating the effectiveness of Medicsight ColonCAD for the detection of colorectal cancer in symptomatic patients. The study was presented on March 9, 2007 at the European Congress of Radiology (ECR) in Vienna, Austria by Professor Steve Halligan from University College Hospital, London.
Professor Halligan has been investigating the relatively unexplored area of CAD detection for colorectal cancers in symptomatic patients. In his ECR presentation, Professor Halligan provided the preliminary results from an ongoing study investigating the potential for CAD to detect colon cancers demonstrated on CT colonography. Many other studies have shown the value of ColonCAD, and this study supports the expansion of the clinical usage of ColonCAD, which has increasingly been advocated for the detection of adenomatous polyps in asymptomatic patients.
The study investigated 59 patients, each with proven cancers established by colonoscopy and histology. These patients were examined with Medicsight ColonCAD to analyze paired prone and supine datasets over a range of four user adjustable CAD filter settings. Across the range of settings, ColonCAD detected 47 to 54 of the 59 cancers (sensitivity range of 88.7% - 91.5%).
Overall, the study showed Medicsight ColonCAD to be very effective in the detection of colon cancer on CT colonography. Both prone and supine datasets are required for optimal CAD results.
David Sumner, chief executive officer of Medicsight plc, commented, "We are pleased with the findings of this study focusing on colorectal cancers in symptomatic patients. These exciting preliminary results validate and could further extend the potential use of the Medicsight Colon CAD in clinical practice."
About MGT Capital Investments, Inc.
MGT Capital Investments is an investment company with two direct subsidiaries that focus solely on the dynamic and consolidating HCIT sector. The first subsidiary, Medicsight plc, is a leading developer of computer-aided detection (CAD) and computer assisted reader (CAR) software solutions that are tested using one of the world's largest databases of verified CT scan data. Medicsight's CAD and CAR products help clinicians identify, measure, and analyze suspicious pathology, such as colorectal polyps and lung lesions. MGT Capital Investments has invested in and controls a second subsidiary, Medicexchange plc, which operates Medicexchange.com, an online multi-vendor sales channel for diagnostic, treatment and surgery planning solutions for cardiac, thoracic, breast imaging, orthopedic, and gastro intestinal imaging. Medicexchange.com provides these solutions in a low-cost, on-demand and downloadable format, enhancing access to information and products for medical imaging professionals. Additional information can be found at www.mgtci.com.
All forward-looking statements are made pursuant to the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Forward- looking statements are based on current management expectations that involve risks and uncertainties that may result in such expectations not being realized. Potential risks and uncertainties include, but are not limited to, the risks described in company filings with the Securities and Exchange Commission.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.